ATTENTION: Please enable Javascript in your browser for full site functionality.
Skip to navigation Skip to main content Skip to footer

Ticker Update

Updates

SUB-TYPE:

Vitabiotics products now exclusively available to order from Alliance Healthcare

We are pleased to announce that from 1 September 2020, Alliance Healthcare will become the sole wholesaler to supply the Vitabiotics product range of nutrition support and supplements from the UK's number one vitamin company to all pharmacies, hospitals and dispensing doctors in the UK.This is the first solus Health & Beauty OTC agreement in the UK and a very exciting partnership for Alliance Healthcare and Vitabiotics.

 

Purchases of Vitabiotics products will arrive as part of your usual Alliance Healthcare delivery service and willnot be subject to Alliance Healthcare's low spend surcharge, if purchased in isolation. In order to receive the products from 1 September, order from Alliance Healthcare in your usual manner. There will be no changes to the current delivery service for the Vitabiotics product portfolio.

 

If you would like to discuss these changes in more detail, please contact your Alliance Healthcare Account Manager.

 

Click here to purchase your Vitabiotics products through our Alliance Healthcare Portal.  

SUB-TYPE:

Standing shoulder to shoulder

Julian Mount, Managing Director, Alliance Healthcare has been speaking with Pharmacy Business magazine and its editor Priyankur Mandav, about the remarkable way Alliance Healthcare has supported community pharmacy during Covid-19 and operates as the backbone of the NHS.

 

In an exclusive interview with Pharmacy Business magazine, a UK leading pharmacy publication with a print circulation of 10,300, Julian reflects on the remarkable way community pharmacy teams have responded to the Covid-19 pandemic:

 

 "Together with community pharmacy, we are the backbone of the NHS and Alliance Healthcare UK supplies one in every three medicines taken in the UK. 

 

 "We knew we had to do everything possible to ensure medicine supply for UK patients; we certainly embraced the challenge and supported the incredible efforts of community pharmacy, the frontline heroes of the coronavirus pandemic.

 

 "We decided not to furlough our field-based teams to allow us to maintain essential contact with community pharmacy and continue our support. I feel the Covid-19 pandemic has strengthened our already robust relationship and together we have stood shoulder to shoulder with community pharmacy throughout the pandemic, when other healthcare professions closed their doors."

 

Read the guest column here.

SUB-TYPE: CLASS 2 RECALL

Class 2 FMD Recall on Vimpat 100mg Tablets & Neupro 4mg/24 Hour Transdermal Patches

We have been notified of an issue whereby several affected batches of the products from the parallel distributors (repackers) in the link below have been found to have mismatched unique pack numbers on the Bollino label (a security and safety feature on the outer packaging). The unique pack numbers on the bollino label should be identical.

 

Please visit the: MHRA website for more details on this drug alert.

 

The affected products' details are as follows:

.
PIP CodeProduct DescriptionSupplierAffected Batch
8386492PI VIMPAT TAB 100MGVARIOUS, PLEASE REFER TO THE ABOVE LINKVARIOUS, PLEASE REFER TO THE ABOVE LINK
8121238PI NEUPRO PATCHES 4MGVARIOUS, PLEASE REFER TO THE ABOVE LINKVARIOUS, PLEASE REFER TO THE ABOVE LINK
8449324PI VIMPAT TAB 100MGVARIOUS, PLEASE REFER TO THE ABOVE LINKVARIOUS, PLEASE REFER TO THE ABOVE LINK

Further Information BeachCourse Limited For all enquiries please contact:

Julio Iglesias (Site Manager) on 02088969075 or email at julio.bcourse@btconnect.com.

Orifarm A/S For all enquiries please contact:

Paul Tobin (Responsible Person) on 07583577513 or email at paul.tobin@orifarm.com.
Steven Cross (UK Parallel Import Sales Manager) on 07498975920 or email at steven.cross@orifarm.com.

OPD Laboratories Limited For all enquiries please contact:
Vasanth Samson (Quality Assurance Manager/Responsible Person) on 01923332773 or email at vasanth@sigmapl.com.

Strathclyde Pharmaceuticals Limited For all enquiries please contact:
Derek Cochrane (QA Manager) at dcochrane@munro-group.eu.

Quadrant Pharmaceuticals Limited For all enquiries please contact:
Abdul Butt (Director, Quality & QP) on 07838038063 or email at abdul.butt@maxearn.co.uk.


Lexon (UK) Limited For all enquiries please contact:
Yogesh Patel at yogesh.patel@lexonuk.com

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies. This recall will remain open for 1 month Please note after this date customer returns may still be accepted but customers may not be credited.

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE:

Stirling Anglian Pharmaceuticals – Dual Agreement

From 1 October 2020, Alliance Healthcare UK will become one of the two wholesalers to supply Stirling Anglian Pharmaceutical products to all pharmacies, Hospitals, and dispensing doctors in the United Kingdom.

The other wholesaler in this agreement is Phoenix. If you have any queries, please speak to your Alliance Healthcare Account Manager.

SUB-TYPE: CLASS 4 CAUTION IN USE

Class 4 Caution in Use on Zopiclone 3.75mg & 7.5mg Tablets

Ratiopharm UK Limited and Generics [UK] Limited t/a Mylan have confirmed that the Patient Information Leaflet (PIL) within all packs and the Summary of Product Characteristics (SmPC) for Ratiopharm is missing important safety information related to potential suicide risks.

 

Please visit the: MHRA website for more details on this drug alert.

 

The affected products' details are as follows:

PIP CodeProduct DescriptionLiveryAffected Batch

1110980ZOPICLONE TAB 3.75MGRatiopharm UK Limited and Generics [UK] Limited t/a MylanALL STOCK

1073626ZOPICLONE TAB 3.75MGRatiopharm UK Limited and Generics [UK] Limited t/a MylanALL STOCK

1076074ZOPICLONE TAB 3.75MGRatiopharm UK Limited and Generics [UK] Limited t/a MylanALL STOCK

1073584ZOPICLONE TAB 7.5MGGenerics [UK] Limited t/a MylanALL STOCK

1110998ZOPICLONE TAB 7.5MGGenerics [UK] Limited t/a MylanALL STOCK

1073618ZOPICLONE TAB 7.5MGGenerics [UK] Limited t/a MylanALL STOCK

8094740ZOPICLONE TAB 3.75MGRatiopharm UK Limited and Generics [UK] Limited t/a MylanALL STOCK

8094757ZOPICLONE TAB 7.5MGGenerics [UK] Limited t/a MylanALL STOCK

For more information or medical information queries, please contact: Ratiopharm UK Limited Teva UK Medical Information at: medinfo@tevauk.com or Tel No: 0207 540 7117

Generics [UK] Limited t/a Mylan Medical Information Direct Line +44 (0)1707 853 000 select option 1, Customer Care direct lin+44 (0)1707 853 000 select option 2 or via Medical Information e-mail info@mylan.co.uk

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

 

This may have been supplied by AHDL. Unfortunately we are not providing specific batch information you will be required to follow the instructions as per the drug alert.

 

This is a caution in use only we are not accepting stock returns.

 

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 3 RECALL

Class 3 Recall on Amlodipine 10mg Tablets

Accord Healthcare Limited is recalling the below batch of Amlodipine 10mg Tablets as a precautionary measure due to out of specification results for tablet description, hardness and average weight obtained during stability testing.

 

Please visit the: MHRA website for more details on this drug alert.

 

The affected products' details are as follows:

PIP CodeProduct DescriptionSupplierAffected Batch
1178177AMLODIPINE TAB 10MGACCORDGY0128
1117969AMLODIPINE TAB 10MGACCORDGY0128
1136175AMLODIPINE TAB 10MGACCORDGY0128
1143353AMLODIPINE TAB 10MGACCORDGY0128
8142705AMLODIPINE TAB 10MGACCORDGY0128

Accord-UK Ltd Medical Information Department Tel: 01271 385257 Email: medinfo@accord-healthcare.com

For stock control enquiries please contact: Accord-UK Ltd Customer Services Team Tel: 0800 373 573

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

 

Please note that Alliance have not supplied the affected batch therefore we are not accepting returns on this recall.

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 4 CAUTION IN USE

Class 4 FMD Recall Various products

The MHRA is currently investigating an incident where several medicines appear to have left the legal supply chain and have then been re-introduced via Kingsley Specials Ltd WDA(H) 49276, who purchased from a company that does not hold a wholesale dealers authorisation and then sold it on to a number of other wholesalers.

 

Please visit the: MHRA website for more details on this drug alert.

 

The affected products' details are as follows:

PIP CodeProduct DescriptionSupplierAffected Batch
6839229Pi Eliquis Tabs 2.5mg 60Drugsrus LtdABF5980
ABF6042
ABG1454
ABG1455
ABG1774
ABG1777
ABH0620
ABH0984
ABH4133
ABH4337
ABH4340
ABJ8246
ABJ8737
Alliance have not suppliedEliquis 5 mg film-coated tabletsPlease refer to attached documentPlease refer to attached document
Alliance have not suppliedEntyvio 300 mg powder for concentrate for solution for infusionPlease refer to attached documentPlease refer to attached document
Alliance have not suppliedFlutiform 250 microgram/10 microgram per actuation pressurised inhalation, suspensionPlease refer to attached documentPlease refer to attached document
Alliance have not suppliedPrivigen 20 g - 100 mg/ml solution for infusionPlease refer to attached documentPlease refer to attached document
Alliance have not suppliedSeretide Evohaler 25 microgram/125 microgram per metered dose pressurised inhalation, suspensionPlease refer to attached documentPlease refer to attached document
Alliance have not suppliedSeretide Evohaler 25 microgram/250 microgram per metered dose pressurised inhalation, suspensionPlease refer to attached documentPlease refer to attached document
Alliance have not suppliedStelara 45 mg solution for injection in pre-filled syringePlease refer to attached documentPlease refer to attached document
Alliance have not suppliedStelara 90 mg solution for injection in pre-filled syringePlease refer to attached documentPlease refer to attached document
Alliance have not suppliedStelara 130 mg concentrate for solution for infusionPlease refer to attached documentPlease refer to attached document
Alliance have not suppliedSymbicort® Turbohaler® 200 micrograms/6micrograms inhalation, inhalation powderPlease refer to attached documentPlease refer to attached document
Alliance have not suppliedSynagis 100 mg/1 ml solution for injectionPlease refer to attached documentPlease refer to attached document
Alliance have not suppliedTysabri 300 mg concentrate for solution for infusionPlease refer to attached documentPlease refer to attached document
Alliance have not suppliedZebinix 800mg tabletsPlease refer to attached documentPlease refer to attached document

We will only be accepting Stock returns on PIP 6839229 Pi Eliquis Tabs 2.5mg 60 we are only able to accept stock back that is inactive or stolen stock.

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Company contacts for further information Smartway Pharmaceuticals Limited • Email: regulatory@smartwaypharma.co.uk • Telephone: 020 8545 7743 Drugsrus Limited • Email: recall@drugsrus.co.uk • Telephone: 020 3397 2347 Optimal Pharma Limited • Email: info@optimalpharma.co.uk • Telephone: 020 3884 0032

 

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 2 RECALL

Class 2 Recall on Oxylan 40mg prolonged-release tablets

GL Pharma is recalling the above batch of Oxylan 40mg prolonged-release tablets due to out of specification results for dissolution obtained during routine stability testing.

 

Please visit the: MHRA website for more details on this drug alert.

 

The affected products' details are as follows:

PIP CodeProduct DescriptionLiveryAffected Batch
6359830OXYCODONE (OXYLAN) PR TAB 40MGGL PHARMA9F119A
3726148OXYCODONE PR TAB 40MG CHANGL PHARMA9F119A

This product is a Schedule 2 Controlled Drug, so please use the Returns Portal for any recalled stock you may need to return to ensure there is authorisation to return. If you are unable to use the Returns Portal then your Alliance Healthcare driver will have a ‘Specialist Product Recall Book' with them on Wednesday 2nd September and Thursday 3rd September for completion and product uplift AM ONLY. Due to Covid 19, the driver will complete the form on your behalf. They will ask for the quantity of stock you have to return and the name of the pharmacist. The driver will give you a copy of the completed form for your records. If you need to return recalled stock from 4th September and are unable to use the Returns Portal please call Customer Services for authorisation to return.

Further Information

For medical information enquiries please contact pv@gl-pharma.at

For stock control enquiries please contact david.hammond@healthcarepharma.co.uk

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CORPORATE NEWS

Alliance Healthcare ‘Returns’ to become Mandatory on the Portal

Alliance Healthcare continues to help our customers self-serve by driving forward adoption of our digital processes via the myahportal (Alliance Healthcare Portal)  and phasing out the paper return notes process entirely.  From Monday 14 September customers should only be processing returns claims through ‘Returns' via the myahportal.

 

The portal provides customers with a simplified approach to access multiple Alliance Healthcare systems and order products online, including surgical orders from NWOS and other functionalities.   

 

As part of our digital evolution of using ‘Returns' online, customers will see the following benefits:

 

- Saves time – automatically completes sections of the returns note for you e.g. name and address details, along with product searches

- Visibility of returns claims online – for ease of reference

- Efficient process - No need to call Customer Service, authorisation to return specialist handling products* can be completed on line. (*a few exceptions apply)

- One claim for all - no need to separate out product types when submitting claims

- Guidance on specific product returns  -  clearly explains what to do if you have faulty items, quality issues and recalls

- Removes confusion – clear information on our terms & conditions for returning products

- Access from anywhere – you just need to be online
 

Over 13,000 customers have now registered with myahportal. Marta from Ashtons Hospital Pharmacy, Brighton said: "It is very easy to fill all the necessary fields and the reference return number given at the end keeps my files in order. I am very pleased that Alliance Healthcare keeps trying to improve their ways of working and that they are listening to their Customer's feedback."

 

The portal is accessible at www.myahportal.co.uk and customers can self-register in just a few minutes.

 

To support customers during the registration and in using the portal, a ChatBot system has been enabled that offers instant question and answer support for the user. Online support is also available via email at: customerportal@alliance-healthcare.co.uk, and a helpline on 0330 100 0448 - option 8, for any technical support and assistance.

 

The old paper ‘Returns' system will close from 13 September.

SUB-TYPE: CLASS 2 RECALL

Class 2 Recall on Fasturtec® 7.5 mg. 1.5 mg/ml

Sanofi has informed us of an Out Of Specification (OOS) result which was detected for Rasburicase enzyme activity according to a specific method and specifications for US market, at 12 months stability time point. Sanofi is recalling Fasturtec® 7.5 mg (Rasburicase) Solution for IV infusion - 7.5 mg/5 ml (Injectable powder in vial packaged with 5 ml solvent in ampoule), batch number A9306 as a precautionary measure.

 

Please visit the: MHRA website for more details on this drug alert.

 

The affected products' details are as follows:

PIP CodeProduct DescriptionSupplierAffected Batch
3338928Fasturtec® 7.5 mg. 1.5 mg/ml powder and solvent for concentrate for solution for infusionSanofiA9306

For medical information enquiries please contact uk-medicalinformation@sanofi.com Med Info Phone :0800 035 25 25.

For stock control enquiries please contact GB-CustomerServices@sanofi.com Phone number: 0800 854 430

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

 

Please note that Alliance Healthcare do not stock and we are not accepting stock returns.

If you have any questions, then please contact your local Service Centre Customer Services team.